Ofir Har-Chen is the CEO and Co-Founder of Clutch Security, a leader in Non-Human Identity security and management.

I look forward to enrolling patients into the PEAK-1 trial as soon as it is open.” “The initial data for casdatifan plus cabozantinib in the ARC-20 study have already exceeded the historic ...

These data support the initiation of PEAK-1, a Phase 3 study that will evaluate casdatifan plus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma (ccRCC) patients ...

“We believe the data presented today emphasize the strength, durability and tangible therapeutic potential of our one-time infusion PRAME cell therapy, IMA203, in this patient populatio ...

Enterome SA, a clinical-stage company developing first-in-class OncoMimics™ immunotherapies to treat cancer, announces it will present new positive data from its ongoing Phase ... memory T cells ...

JPA (Hibernate) Hibernate ORM enables developers to more easily write applications whose data outlives the application process. Swing Provides a set of "lightweight" (all-Java language) components ...

New data from the Phase III PEACE III trial showed that XOFIGO ... Global Product Strategy and Commercialization and Member of the Pharmaceuticals Leadership Team at Bayer. About PEACE III (EORTC GUCG ...

Javascript must be enabled to use this site. Please enable Javascript in your browser and try again. Take control of student loan debt! Sign up for a free, live ...